ImmunityBio Reports Third Quarter Revenue and EPS Misses
ImmunityBio (IBRX) reported third-quarter financial results that fell short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.18, missing estimates by $0.10. While revenue grew significantly by 52.3% year-over-year to reach $48.84 million, this figure missed analyst projections by approximately $10.39 million. The results come amid ongoing scrutiny regarding the commercial execution of its bladder cancer treatment, Anktiva. Despite recent regulatory milestones and expanded FDA approvals for Anktiva in non-muscle invasive bladder cancer (NMIBC), market sentiment remains cautious as investors weigh the company's rapid revenue growth against its ability to meet high performance expectations.
Tickers: $IBRX
Topics: earnings miss financial results GAAP EPS revenue growth